
Search News
-
Published on 16:51 GMTSource: Endpoints News - Neutral
-
Published on 07:52 GMT
AstraZeneca’s ‘smoker’s lung’ therapy meets main goals of late-stage asthma trials
(Reuters) -AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for uncontrolled asthma, showing clinically meaningful improvement in lung function. The Anglo-Swedish drugmaker’s therapy, …
Source: KFGO - North Dakota - Neutral -
Published on 05:02 GMT
AstraZeneca Korea, Oncosoft team up to enhance NF1 treatment with AI
AstraZeneca Korea said Friday that it has signed a memorandum of understanding (MOU) with AI-based software startup Oncosoft to enhance the diagnosis and assessment of the rare disease neurofibromatosis type 1 (NF1). The agreement seeks to expand treatment …
Source: Korea Biomedical Review - Neutral -
Published on May 1, 2025
AstraZeneca quietly exits neuroscience
AstraZeneca on Tuesday confirmed it has closed down its neuroscience research group to direct resources toward more “high value” projects. On an earnings call with investors, Sharon Barr, AstraZeneca’s head of biopharmaceuticals research and development, …
Source: BioPharma Dive - Pending -
Published on May 1, 2025
This Week’s Biopharma News: AstraZeneca Cans Phase III Trial
Credit: Adobestock.com The big business announcements: AstraZeneca axes phase III prostate cancer trial AstraZeneca is discontinuing a phase III trial of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) in …
Source: The Medicine Maker - Neutral -
Published on May 1, 2025
AstraZeneca’s AI lung cancer screening program executes 5 mn tests, flags 50k individuals at high risk
New Delhi: UK pharma major AstraZeneca in partnership with health-tech company Qure.ai, announced the completion of 5 million artificial intelligence (AI) enabled chest X-rays (CXRs) across more than 20 countries in Asia, the Middle East, Africa, and Latin …
Source: ETHealthworld.com - Center-right -
Published on May 1, 2025
AstraZeneca, Qure.ai complete AI-enabled assessment of 5 million chest X-rays for lung cancer
Image used for representation purpose only. | Photo Credit: x-reflexnaja AstraZeneca and health-tech company Qure.ai have completed the risk assessment of 5 million artificial intelligence (AI)-enabled chest X-rays (CXRs) across more than 20 countries in …
Source: The Hindu Business Line - Neutral -
Published on May 1, 2025
Up 7.5% in a week! Is the GSK share price about to do an AstraZeneca?
When I first started writing for The Motley Fool more than two decades ago, the GSK (LSE: GSK) share price was a FTSE 100 shining light. In my recollection, GlaxoSmithKline, as it was known then, even outshone pharmaceutical sector rival AstraZeneca (LSE: …
Source: The Motley Fool UK - Neutral -
Published on May 1, 2025
AstraZeneca’s share price is down 20% from September, so is it time for me to buy?
AstraZeneca’s (LSE: AZN) share price has fallen significantly from its 3 September one-year traded high of £133.38. Some of this drop resulted from an investigation of its Chinese business. The firm said in its Q1 2025 results released on 29 April that …
Source: The Motley Fool UK - Neutral -
Published on May 1, 2025
AstraZeneca Faces Intensified Probe in China as Tax Evasion Amount Grows
British-Swedish pharmaceutical giant AstraZeneca plc is facing increasing scrutiny in China, with authorities accusing the company of evading more than $1.6 million in import taxes as part of a widening smuggling investigation that now includes a top- …
Source: Caixin - Indeterminate